Evotec SE
EVO · XNASCIK 1412558fmd_10FQS8NVZEZ73SQ3KEY1NXKK5DManufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 01, 2019 to Dec 31, 2025, 7 periods
Latest annual · FY2024
Millions- Total revenues
- 797
- Gross profit
- 115
- Operating income
- (143)
- Net income
- (196)
- Free cash flow
- (99)
Daily close · EVOIEX trades only
Oct 16, 2025 to Nov 11, 2026 · 250 sessions1.70 USD
Built from trades executed at IEX only, one exchange with a small share of US volume. This is not the consolidated tape. The close is the last IEX trade of the session, not the official closing price. Earlier sessions are divided by the later split ratios the API confirmed against IEX prices; dividends are not adjusted. Switch to As traded for the prices as they printed. End of day, not real time: a session is published the day after it trades.
Data provided for free by IEX. By accessing or using IEX Historical Data, you agree to the IEX Historical Data Terms of Use. iex.io/legal/hist-data-terms
Key stats
Open AnalysisCompound annual growth
- Revenue, 3 yearsFY2021 to FY2024
- +8.8%
- Revenue, 5 yearsFY2019 to FY2024
- +12.3%
- Net income, 5 yearsFY2019 to FY2024
- n/m
Evotec SE (EVO) financials: quick answers
Annual figures as filed with the SEC. Each number links to the filing it came from and to its proof.
| Metric | FY2024 | FY2023 | Change | Source |
|---|---|---|---|---|
| Revenue | €797 million | €781.4 million | +2% | 20-F 2025-04-17 · proof |
| Gross profit | €114.9 million | €175.1 million | -34.4% | 20-F 2025-04-17 · proof |
| Operating income | -€142.5 million | -€47.5 million | 20-F 2025-04-17 · proof | |
| Net income | -€196.1 million | -€83.9 million | 20-F 2025-04-17 · proof | |
| Cash from operating activities | €18.2 million | €36.4 million | -50% | 20-F 2025-04-17 · proof |
| Free cash flow | -€99.2 million | -€176.9 million | 20-F 2025-04-17 · proof | |
| Total assets | €1.9 billion | €2.3 billion | -15.1% | 20-F 2025-04-17 · proof |
| Total liabilities | €960 million | €1.1 billion | -15.2% | 20-F 2025-04-17 · proof |
| Cash and cash equivalents | €306.4 million | €510.9 million | -40% | 20-F 2025-04-17 · proof |
- What was Evotec SE (EVO)'s revenue in fiscal 2024?
- Evotec SE (EVO) reported revenue of €797 million for fiscal 2024 (the year ended Dec 31, 2024), against €781.4 million the year before (+2%). Source: the 20-F filed with the SEC on Apr 17, 2025. SEC
- What was Evotec SE (EVO)'s gross profit in fiscal 2024?
- Evotec SE (EVO) reported gross profit of €114.9 million for fiscal 2024 (the year ended Dec 31, 2024), against €175.1 million the year before (-34.4%). Source: the 20-F filed with the SEC on Apr 17, 2025. SEC
- What was Evotec SE (EVO)'s operating income in fiscal 2024?
- Evotec SE (EVO) reported operating income of -€142.5 million for fiscal 2024 (the year ended Dec 31, 2024), against -€47.5 million the year before. Source: the 20-F filed with the SEC on Apr 17, 2025. SEC
- What was Evotec SE (EVO)'s net income in fiscal 2024?
- Evotec SE (EVO) reported net income of -€196.1 million for fiscal 2024 (the year ended Dec 31, 2024), against -€83.9 million the year before. Source: the 20-F filed with the SEC on Apr 17, 2025. SEC
- What was Evotec SE (EVO)'s cash from operating activities in fiscal 2024?
- Evotec SE (EVO) reported cash from operating activities of €18.2 million for fiscal 2024 (the year ended Dec 31, 2024), against €36.4 million the year before (-50%). Source: the 20-F filed with the SEC on Apr 17, 2025. SEC
- What was Evotec SE (EVO)'s free cash flow in fiscal 2024?
- Evotec SE (EVO) reported free cash flow of -€99.2 million for fiscal 2024 (the year ended Dec 31, 2024), against -€176.9 million the year before. Source: the 20-F filed with the SEC on Apr 17, 2025. SEC
- What are Evotec SE (EVO)'s total assets?
- As of Dec 31, 2024, Evotec SE (EVO) reported total assets of €1.9 billion, against €2.3 billion a year earlier (-15.1%). Source: the 20-F filed with the SEC on Apr 17, 2025. SEC
- What are Evotec SE (EVO)'s total liabilities?
- As of Dec 31, 2024, Evotec SE (EVO) reported total liabilities of €960 million, against €1.1 billion a year earlier (-15.2%). Source: the 20-F filed with the SEC on Apr 17, 2025. SEC
- What are Evotec SE (EVO)'s cash and cash equivalents?
- As of Dec 31, 2024, Evotec SE (EVO) reported cash and cash equivalents of €306.4 million, against €510.9 million a year earlier (-40%). Source: the 20-F filed with the SEC on Apr 17, 2025. SEC
Read from the FinancialMD API on Nov 13, 2026. Values change only when a new filing is made; see the Financials tab for every period and as-of replay.
The same numbers for an agent, with proof on every value:
curl "https://api.financial.md/v1/company/financials/income_statement/standardized?company=ticker:EVO&period_type=annual&limit=5"Information only, not investment advice.